Gene expression analysis of aberrant signaling pathways in meningiomas

Torres‑Martín,Miguel; Martinez‑Glez,Victor; Peña‑Granero,Carolina; Isla,Alberto; Lassaletta,Luis; De Campos,Jose  M.; Pinto,Giovanny  R.; Burbano,Rommel  R.; Meléndez,Bárbara; Castresana,Javier  S.; Rey,Juan  A.

doi:10.3892/ol.2013.1363

Gene expression analysis of aberrant signaling pathways in meningiomas

Authors:
- Miguel Torres‑Martín
- Victor Martinez‑Glez
- Carolina Peña‑Granero
- Alberto Isla
- Luis Lassaletta
- Jose M. De Campos
- Giovanny R. Pinto
- Rommel R. Burbano
- Bárbara Meléndez
- Javier S. Castresana
- Juan A. Rey
View Affiliations

Affiliations: Neuro-Oncogenetics Laboratory, Research Unit, La Paz University Hospital, IdiPAZ, Madrid, Spain, INGEMM, La Paz University Hospital, IdiPAZ, Madrid, Spain, Neurosurgery Department, La Paz University Hospital, IdiPAZ, Madrid, Spain, Department of Otolaryngology, La Paz University Hospital, IdiPAZ, Madrid, Spain, Fundación Jiménez Díaz, Madrid, Spain, Genetics and Molecular Biology Laboratory, Federal University of Piauí, Parnaibá, Brazil, Human Cytogenetics Laboratory, Federal University of Pará, Belem, Brazil, Molecular Pathology Research Unit, Virgen de la Salud Hospital, Toledo, Spain, Brain Tumor Biology Unit, University of Navarra, Pamplona, Spain
Published online on: May 23, 2013 https://doi.org/10.3892/ol.2013.1363
Pages: 275-279

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Examining aberrant pathway alterations is one method for understanding the abnormal signals that are involved in tumorigenesis and tumor progression. In the present study, expression arrays were performed on tumor‑related genes in meningiomas. The GE Array Q Series HS‑006 was used to determine the expression levels of 96 genes that corresponded to six primary biological regulatory pathways in a series of 42 meningiomas, including 32 grade I, four recurrent grade I and six grade II tumors, in addition to three normal tissue controls. Results showed that 25 genes that were primarily associated with apoptosis and angiogenesis functions were downregulated and 13 genes frequently involving DNA damage repair functions were upregulated. In addition to the inactivation of the neurofibromin gene, NF2, which is considered to be an early step in tumorigenesis, variations of other biological regulatory pathways may play a significant role in the development of meningioma.

View Figures

View References

1.	Perry A, Louis DN, Scheithauer BW, et al: Meningiomas. Pathology and Genetics of Tumours of the Nervous System. World Health Organization Classification of Tumors. Kleihues P and Cavenee WK: 2nd edition. IARC Press; Lyon, France: pp. 164–172. 2007
2.	Stemmer-Rachaminov AO, Wiestler OD and Louis DN: Neurofibromatosis type 2. Pathology and Genetics of Tumours of the Nervous System. World Health Organization Classification of Tumors. Kleihues P and Cavenee WK: 2nd edition. IARC Press; Lyon, France: pp. 210–214. 2007
3.	Bello MJ, de Campos JM, Kusak ME, et al: Allelic loss at 1p is associated with tumor progression of meningiomas. Genes Chromosomes Cancer. 9:296–298. 1994. View Article : Google Scholar : PubMed/NCBI
4.	Weber R, Boström J, Wolter M, et al: Analysis of genomic alterations in benign, atypical, and anaplastic meningiomas: toward a genetic model of meningioma progression. Proc Natl Acad Sci USA. 94:14719–14724. 1997. View Article : Google Scholar : PubMed/NCBI
5.	Leone PE, Bello MJ, de Campos JM, et al: NF2 gene mutations and allelic status of 1p, 14q, and 22q in sporadic meningiomas. Oncogene. 18:2231–2239. 1999. View Article : Google Scholar : PubMed/NCBI
6.	Mendiola M, Bello MJ, Alonso J, et al: Search for mutations of the hRAD54 geen in sporadic meningiomas with deletion at 1p32. Mol Carcinog. 24:300–304. 1999. View Article : Google Scholar : PubMed/NCBI
7.	Lomas J, Bello MJ, Arjona D, et al: Analysis of p73 gene in meningiomas with deletion at 1p. Cancer Genet Cytogenet. 129:88–91. 2001. View Article : Google Scholar : PubMed/NCBI
8.	Bello MJ, Amiñoso C, Lopez-Marin I, et al: DNA methylation of multiple promoter-associated CpG islands in meningiomas: relationship with the allelic status at 1p and 22q. Acta Neuropathol. 108:413–421. 2004. View Article : Google Scholar : PubMed/NCBI
9.	Liu Y, Pang JC, Dong S, et al: Aberrant CpG island hyper-methylation profile is associated with atypical and anaplastic meningiomas. Hum Pathol. 36:416–425. 2005. View Article : Google Scholar : PubMed/NCBI
10.	Lomas J, Amiñoso C, Gonzalez-Gomez P, et al: Methylation status of TP73 in meningiomas. Cancer Genet Cytogenet. 148:148–151. 2004. View Article : Google Scholar : PubMed/NCBI
11.	Lomas J, Bello MJ, Arjona D, et al: Genetic and epigenetic alteration of the NF2 gene in sporadic meninigomas. Genes Chromosomes Cancer. 42:314–319. 2005. View Article : Google Scholar : PubMed/NCBI
12.	Pérez-Magán E, Rodríguez de Lope A, Ribalta T, et al: Differential expression profiling analyses identifies downregulation of 1p, 6q, and 14q genes and overexpression of 6p histone cluster 1 gene as markers of recurrence in meningiomas. Neuro Oncology. 12:1278–1290. 2010.
13.	Tseng KY, Chung MH, Sytwu HK, et al: Osteopontin expression is a valuable marker for prediction of short-term recurrence in WHO grade I benign meningiomas. J Neurooncol. 100:217–223. 2010. View Article : Google Scholar : PubMed/NCBI
14.	Aarhus M, Lund-Juhansen M and Knappskog PM: Gene expression profiling of meningiomas: current status after a decade of microarray-based transcriptomic studies. Acta Neurochir (Wien). 153:447–456. 2011. View Article : Google Scholar
15.	Pérez-Magán E, Campos-Martín Y, Mur P, et al: Genetic alterations associated with progression and recurrence in meningiomas. J Neuropathol Exp Neurol. 71:882–893. 2012.PubMed/NCBI
16.	Sayagués JM, Tabernero MD, Maillo A, et al: Microarray-based analysis of spinal versus intracranial meningiomas: different clinical, biological, and genetic characteristics associated with distinct patterns of gene expression. J Neuropathol Exp Neurol. 65:445–454. 2006.
17.	Martinez-Glez V, Franco-Hernandez C, Alvarez L, et al: Meningiomas and schwannomas: Molecular subgroup classification found by expression arrays. Int J Oncol. 34:493–504. 2009.PubMed/NCBI
18.	Martínez-Glez V, Alvarez L, Franco-Hernández C, et al: Genomic deletions at 1p and 14q are associated with an abnormal cDNA microarray gene expression pattern in meningiomas but not in schwannomas. Cancer Genet Cytogenet. 196:1–6. 2010.PubMed/NCBI
19.	Ragel BT and Jensen RL: Aberrant signalling pathways in meningiomas. J Neurooncol. 99:315–324. 2010. View Article : Google Scholar : PubMed/NCBI
20.	Torres-Martín M, Martinez-Glez V, Peña-Granero C, et al: Expression analysis of tumor-related genes involved in critical regulatory pathways in schwannomas. Clin Transl Oncol. 15:409–411. 2013.